$AGIO
Agios Pharmaceuticals Inc Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000143922218000004 Filed on February 14, 2018

Income Statement

Concept	2018 Q1	2017 Q2	2017
Revenue	$8.762M	$11.35M	$43.01M
YoY Change	-16.62%	62.6%	-38.46%
Cost Of Revenue	$0.00		$0.00
YoY Change
Gross Profit	$8.762M		$43.01M
YoY Change			-38.46%
Gross Profit Margin	100.0%		100.0%
Selling, General & Admin	$24.55M	$16.13M	$71.12M
YoY Change	65.65%	27.61%	40.25%
% of Gross Profit	280.19%		165.36%
Research & Development	$78.22M	$79.82M	$292.7M
YoY Change	24.7%	57.11%	32.94%
% of Gross Profit	892.76%		680.48%
Depreciation & Amortization	$1.725M	$1.600M	$6.432M
YoY Change	8.42%	14.29%	12.84%
% of Gross Profit	19.69%		14.95%
Operating Expenses	$102.8M	$95.95M	$363.8M
YoY Change	32.52%	51.22%	34.31%
Operating Profit	-$94.01M	-$84.60M	-$320.8M
YoY Change	40.22%	49.81%	59.61%
Interest Expense	$3.190M	$1.520M	$6.100M
YoY Change	262.5%	192.31%	144.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$90.83M	-$83.08M	-$290.4M
YoY Change	37.27%	48.49%	46.33%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$90.83M	-$83.08M	-$314.7M
YoY Change	37.27%	48.49%	58.55%
Net Earnings / Revenue	-1036.58%	-732.26%	-731.6%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.631M	-$1.777M	-$6.753M
COMMON SHARES
Basic Shares Outstanding	57.33M shares	48.20M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q2	2017
SHORT-TERM ASSETS
Cash & Short-Term Investments	$782.5M	$586.0M	$423.9M
YoY Change	63.09%	25.92%	-21.69%
Cash & Equivalents	$364.5M	$138.7M	$102.7M
Short-Term Investments	$418.0M	$447.3M	$321.2M
Other Short-Term Assets	$15.60M	$13.00M	$17.50M
YoY Change	25.81%	46.07%	69.9%
Inventory
Prepaid Expenses
Receivables	$1.400M		$1.200M
Other Receivables	$3.500M		$2.600M
Total Short-Term Assets	$803.0M	$604.7M	$445.3M
YoY Change	58.42%	24.89%	-20.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.73M	$24.77M	$24.40M
YoY Change	-1.69%	-1.44%	-3.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$212.3M	$129.9M	$143.8M
YoY Change	807.26%	176.97%	345.2%
Other Assets	$1.104M	$1.249M	$900.0K
YoY Change	-61.77%	-9.62%	-43.75%
Total Long-Term Assets	$237.1M	$155.9M	$169.1M
YoY Change	370.04%	112.3%	185.64%
TOTAL ASSETS
Total Short-Term Assets	$803.0M	$604.7M	$445.3M
Total Long-Term Assets	$237.1M	$155.9M	$169.1M
Total Assets	$1.040B	$760.6M	$614.4M
YoY Change	86.63%	36.41%	-0.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.93M	$23.41M	$22.80M
YoY Change	11.02%	26.89%	33.33%
Accrued Expenses	$17.01M	$29.64M	$34.00M
YoY Change	-32.29%	105.64%	6.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$74.70M	$93.65M	$94.90M
YoY Change	-9.38%	39.22%	7.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$99.80M	$158.0M	$144.0M
YoY Change	-40.42%	-21.51%	-16.33%
Total Long-Term Liabilities	$99.80M	$158.0M	$144.0M
YoY Change	-40.42%	-21.51%	-16.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$74.70M	$93.65M	$94.90M
Total Long-Term Liabilities	$99.80M	$158.0M	$144.0M
Total Liabilities	$174.5M	$251.6M	$238.9M
YoY Change	-30.16%	-6.29%	-8.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$758.6M	-$632.6M
YoY Change	38.04%	73.88%
Common Stock	$1.718B	$1.142B
YoY Change	100.39%	75.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$865.6M	$509.0M	$375.5M
YoY Change
Total Liabilities & Shareholders Equity	$1.040B	$760.6M	$614.4M
YoY Change	86.63%	36.41%	-0.76%

Cashflow Statement

Concept	2018 Q1	2017 Q2	2017
OPERATING ACTIVITIES
Net Income	-$90.83M	-$83.08M	-$314.7M
YoY Change	37.27%	48.49%	58.55%
Depreciation, Depletion And Amortization	$1.725M	$1.600M	$6.432M
YoY Change	8.42%	14.29%	12.84%
Cash From Operating Activities	-$99.00M	-$59.00M	-$285.2M
YoY Change	33.65%	-137.39%	-839.67%
INVESTING ACTIVITIES
Capital Expenditures	$1.432M	-$1.000M	$4.627M
YoY Change	388.74%	-64.29%	-53.33%
Acquisitions
YoY Change
Other Investing Activities	-$166.1M	-$274.6M	-$53.28M
YoY Change	-251.28%	-813.25%	-51.32%
Cash From Investing Activities	-$167.5M	-$275.8M	-$57.91M
YoY Change	-252.92%	-872.55%	-51.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$516.2M	$270.2M	$270.3M
YoY Change			66.67%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$528.3M	273.2M	$285.1M
YoY Change	12956.77%	18113.33%	67.93%
NET CHANGE
Cash From Operating Activities	-$99.00M	-59.00M	-$285.2M
Cash From Investing Activities	-$167.5M	-275.8M	-$57.91M
Cash From Financing Activities	$528.3M	273.2M	$285.1M
Net Change In Cash	$261.7M	-61.60M	-$58.03M
YoY Change	562.24%	-131.59%	-165.21%
FREE CASH FLOW
Cash From Operating Activities	-$99.00M	-$59.00M	-$285.2M
Capital Expenditures	$1.432M	-$1.000M	$4.627M
Free Cash Flow	-$100.4M	-$58.00M	-$289.9M
YoY Change	35.05%	-136.11%	-1111.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	20266000	USD
CY2017Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	14849000	USD
CY2016	agio	Available For Sale Securities Non Current Minimum Liquidating Period AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod	P12M
CY2015	agio	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitPercent	-0.0180
CY2016	agio	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitPercent	-0.0180
CY2017	agio	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitPercent	0.0030
CY2015	agio	Effective Income Tax Rate Reconciliation Tax Credits Adjustments EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments	0.0840
CY2016	agio	Effective Income Tax Rate Reconciliation Tax Credits Adjustments EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments	0.0950
CY2017	agio	Effective Income Tax Rate Reconciliation Tax Credits Adjustments EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments	0.1040
CY2015	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	1733000	USD
CY2017	agio	Available For Sale Securities Non Current Minimum Liquidating Period AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod	P12M
CY2016Q4	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	4886000	USD
CY2017Q4	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	2448000	USD
CY2016	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	-3339000	USD
CY2017	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	-2438000	USD
CY2015	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	0	USD
CY2016	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	0	USD
CY2017	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	1222000	USD
CY2011	agio	Number Of Changes In Stockholders Ownership NumberOfChangesInStockholdersOwnership	2	Ownership
CY2017Q4	agio	Number Of Legal Proceedings That Have Material Effect NumberOfLegalProceedingsThatHaveMaterialEffect	0	Lawsuit
CY2016	agio	Number Of States Federal Or Foreign In Auditing Process NumberOfStatesFederalOrForeignInAuditingProcess	0	Audit
CY2017	agio	Number Of States Federal Or Foreign In Auditing Process NumberOfStatesFederalOrForeignInAuditingProcess	0	Audit
CY2017	agio	Percentage Of Increase In Stockholders Ownership PercentageOfIncreaseInStockholdersOwnership	0.05
CY2017	agio	Percentage Of Stockholders Ownership Increase PercentageOfStockholdersOwnershipIncrease	0.50
CY2017	agio	Period Of Change In Stockholders Ownership PeriodOfChangeInStockholdersOwnership	P3Y
CY2017	agio	Period Under Agreement To Receive Discounted Upfront Labor Costs By Service Provider PeriodUnderAgreementToReceiveDiscountedUpfrontLaborCostsByServiceProvider	P5Y
CY2015	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	186000	USD
CY2016	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	32000	USD
CY2017	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	0	USD
CY2015	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	0	USD
CY2016	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	230000	USD
CY2017	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	0	USD
CY2016Q4	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	0	USD
CY2017Q4	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	1222000	USD
CY2017	agio	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit	90000000	USD
CY2015	agio	Vesting Of Restricted Stock Value Increase Decrease VestingOfRestrictedStockValueIncreaseDecrease	6000	USD
CY2016	agio	Vesting Of Restricted Stock Value Increase Decrease VestingOfRestrictedStockValueIncreaseDecrease	0	USD
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57326741	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	2154093268	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS INC
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2017	dei	Trading Symbol TradingSymbol	AGIO
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3428000	USD
CY2017Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	169000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17106000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22767000	USD
CY2015	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-539000	USD
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-773000	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	11000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32002000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34031000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	476000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1389000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	842013000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1174904000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	6000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3140000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13372000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19397000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-313000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31574000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-117993000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31963000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42086000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42086000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	47809000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47809000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4641418	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5319948	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5725208	shares
CY2016Q4	us-gaap	Assets Assets	619094000	USD
CY2017Q4	us-gaap	Assets Assets	614397000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	559892000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	445261000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	335400000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	439400000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	380560000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	321212000	USD
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	32250000	USD
CY2017Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	143814000	USD
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	158	security
CY2017Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	240	security
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2163000	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	73000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1011000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14031000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71764000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160754000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102724000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	57733000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	88990000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-58030000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	567800000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42220444	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48826153	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42220444	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48826153	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-198466000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-315746000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	18155000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35913000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	3412000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	301000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	17773000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	37842000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	154297000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	125798000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	8051000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	41243000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4410000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3906000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	216445000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	306464000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	126077000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	131165000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	43350000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	100791000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	22731000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	20539000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	8516000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	5042000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	3310000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	3778000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	208000000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	208033000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	301900000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	301915000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8412000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4549000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2017	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.06
CY2015	us-gaap	Depreciation Depreciation	3342000	USD
CY2016	us-gaap	Depreciation Depreciation	5708000	USD
CY2017	us-gaap	Depreciation Depreciation	6432000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.15
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.47
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.63
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.34
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.07
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.56
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.78
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.75
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.59
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.81
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4460
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4340
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1940
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.2870
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0120
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0190
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0160
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0030
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0030
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0450
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0290
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0400
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11092000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15693000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2016	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2017	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-33000	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-40000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35992000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50714000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	71124000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-111057000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-179896000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-290423000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6674000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-18575000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-24247000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-117731000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-198471000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-314670000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-2930000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	1040000	USD
CY2016	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-275000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4215000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3501000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5329000	USD
CY2015	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	3841000	USD
CY2016	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1633000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	16854000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1522000	USD
CY2015	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-15805000	USD
CY2016	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-1346000	USD
CY2017	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	2729000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-14047000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	165846000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-26570000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3768000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2695000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6530000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	968000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	2514000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	6124000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	7100000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	6000000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	6000000	USD
CY2017Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	2900000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	260503000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	238894000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	619094000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	614397000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	88433000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94941000	USD
CY2015	us-gaap	License And Services Revenue LicenseAndServicesRevenue	59119000	USD
CY2016	us-gaap	License And Services Revenue LicenseAndServicesRevenue	69892000	USD
CY2017	us-gaap	License And Services Revenue LicenseAndServicesRevenue	41074000	USD
CY2016	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2017	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6373000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	169778000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	285110000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	128309000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-119350000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57908000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76949000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	38562000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-285232000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-117732000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-198471000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-314670000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23198000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-55953000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-62834000	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-56486000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66166000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-83082000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-77137000	USD
CY2017Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-88285000	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015	us-gaap	Operating Expenses OperatingExpenses	177819000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	270877000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	363805000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-118700000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-23594000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-56470000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-63512000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-57409000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-200985000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-67047000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-84600000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-79017000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-90130000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-320794000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	95872000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	11295000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	14447000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	12392000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	12077000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	11770000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	33891000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	168000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	349000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1615000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	891000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-261000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1076000	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	207000	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	230000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-638000	USD
CY2015	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	353177000	USD
CY2016	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	506067000	USD
CY2017	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	688702000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20164000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9915000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4627000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10264000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17486000	USD
CY2017Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270200000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	162150000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270250000	USD
CY2015	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6580000	USD
CY2016	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7858000	USD
CY2017	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	14222000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	501650000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	396632000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	635421000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	38709000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	43828000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25337000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24431000	USD
CY2015	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	25173000	USD
CY2016	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	19714000	USD
CY2017	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	7811000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	141827000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	220163000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	292681000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-483151000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-798061000	USD
CY2015	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	59119000	USD
CY2016	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	44892000	USD
CY2017	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	41074000	USD
CY2015	us-gaap	Revenues Revenues	59119000	USD
CY2016Q1	us-gaap	Revenues Revenues	31281000	USD
CY2016Q2	us-gaap	Revenues Revenues	6978000	USD
CY2016Q3	us-gaap	Revenues Revenues	8985000	USD
CY2016Q4	us-gaap	Revenues Revenues	22648000	USD
CY2016	us-gaap	Revenues Revenues	69892000	USD
CY2017Q1	us-gaap	Revenues Revenues	10508000	USD
CY2017Q2	us-gaap	Revenues Revenues	11346000	USD
CY2017Q3	us-gaap	Revenues Revenues	11358000	USD
CY2017Q4	us-gaap	Revenues Revenues	9799000	USD
CY2017	us-gaap	Revenues Revenues	43011000	USD
CY2015	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2016	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2017	us-gaap	Royalty Revenue RoyaltyRevenue	1937000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	31963000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	42086000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	47809000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	7500	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6962
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7284
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7773
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0171
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0142
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0205
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2936068	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	44.32
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	531492	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1620652	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	63559000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	94336000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5218880	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5577562	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	46.79
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.58
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	94336000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5577562	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	49.58
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.42
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	74.48
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	51.78
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y15D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y18D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y18D
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	74229000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M24D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M11D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M9D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y3M9D
CY2017Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5808080.00	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	730478	shares
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	162150000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	270250000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7136000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7703000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14190000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	424366000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	345118000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	358591000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	375503000	USD
CY2017	us-gaap	Stockholders Equity Other StockholdersEquityOther	409000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11263000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	11263000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	52500000	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	86100000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	93900000	USD
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37429262	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39126400	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46587631	shares
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of credit risk</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, and marketable securities. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. </font><font style="font-family:inherit;font-size:10pt;">We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</font></div></div>
CY2017	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of Business</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">References to Agios</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Throughout this Annual Report on Form 10-K, “we,” “us,” and “our,” and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and “our board of directors” refers to the board of directors of Agios Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company committed to the fundamental transformation of patients’ lives through scientific leadership in the field of cellular metabolism, with the goal of making transformative, first- or best-in-class medicines. Our therapeutic areas of focus are cancer and rare genetic diseases, or RGDs, which are diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Most RGDs are often associated with severe or life-threatening features. The incidence of a single RGD can vary widely but is generally very infrequent, usually equal to or less than one per 100,000 births. In both areas of cancer and RGDs, we are seeking to unlock the biology of cellular metabolism as a platform to create transformative therapies.</font><font style="font-family:inherit;font-size:10pt;"> We are located in Cambridge, Massachusetts.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our first commercial cancer product is IDHIFA®. In August 2017, the U.S. Food and Drug Administration, or FDA, granted our collaboration partner Celgene Corporation, or Celgene, approval of IDHIFA® for the treatment of adult patients with relapsed or refractory acute myeloid leukemia, or R/R AML, and an isocitrate dehydrogenase 2, or IDH2, mutation as detected by an FDA-approved test. IDHIFA®, an oral targeted inhibitor of the mutated IDH2 enzyme, is the first and only FDA-approved therapy for patients with R/R AML and an IDH2 mutation.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our most advanced clinical cancer product candidates are ivosidenib, which targets mutated isocitrate dehydrogenase 1, or IDH1, and AG-881, which is a brain-penetrant pan-IDH mutant inhibitor. These mutations are found in a wide range of hematological malignancies and solid tumors. In December 2017, we submitted a new drug application, or NDA, to the FDA for ivosidenib for the treatment of patients with R/R AML and an IDH1 mutation. We plan to submit an Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, for ivosidenib for IDH1 mutant-positive R/R AML in the fourth quarter of 2018.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our next most advanced cancer product candidate is AG-270, an inhibitor of methionine adenosyltransferase 2a, or MAT2A. We submitted an investigational new drug application, or IND, for AG-270 in November 2017, and in December 2017 the FDA concluded that we may proceed with our planned phase 1 dose-escalation trial of AG-270 in multiple tumor types carrying a methylthioadenosine phosphorylase, or MTAP, deletion.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our most advanced preclinical cancer product candidate is an inhibitor of the metabolic enzyme dihydroorotate dehydrogenase, or DHODH. We plan to submit an IND for our DHODH inhibitor for the treatment of hematologic malignancies in the fourth quarter of 2018.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The lead product candidate in our RGD program, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase, or PK, deficiency. PK deficiency is a rare genetic disorder that often results in severe hemolytic anemia, jaundice and lifelong conditions associated with chronic anemia and secondary complications due to inherited mutations in the pyruvate kinase enzyme within red blood cells, or RBCs. We intend to initiate two global, pivotal trials of AG-348 in PK deficiency in the first half of 2018: ACTIVATE-T, a single arm trial of approximately 20 regularly transfused patients, is expected to initiate in the first quarter of 2018, and ACTIVATE, a 1:1 randomized, placebo-controlled trial of approximately 80 patients who do not receive regular transfusions, is expected to initiate in the second quarter of 2018. We also expect to initiate a phase 2 proof of concept trial of AG-348 in thalassemia in the fourth quarter of 2018.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the aforementioned development programs, we are seeking to advance a number of early-stage discovery programs in the areas of cancer metabolism, RGDs and metabolic immuno-oncology, or MIO, a developing field which aims to modulate the activity of relevant immune cells by targeting critical metabolic nodes, thereby, enhancing the immune mediated anti-tumor response.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2017, we completed a public offering of </font><font style="font-family:inherit;font-size:10pt;">5,050,505</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at an offering price of </font><font style="font-family:inherit;font-size:10pt;">$49.50</font><font style="font-family:inherit;font-size:10pt;"> per share. We received net proceeds from this offering of </font><font style="font-family:inherit;font-size:10pt;">$235.0 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions paid by us. In addition, we granted the underwriters the right to purchase up to an additional </font><font style="font-family:inherit;font-size:10pt;">757,575</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, which was exercised in April 2017, resulting in additional net proceeds to us of </font><font style="font-family:inherit;font-size:10pt;">$35.2 million</font><font style="font-family:inherit;font-size:10pt;">, after underwriting discounts and commissions. After giving effect to the full exercise of the over-allotment option, the number of shares sold by us in the public offering totaled </font><font style="font-family:inherit;font-size:10pt;">5,808,080</font><font style="font-family:inherit;font-size:10pt;"> shares, and net proceeds to us totaled </font><font style="font-family:inherit;font-size:10pt;">$270.2 million</font><font style="font-family:inherit;font-size:10pt;">, after underwriting discounts and commissions.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, we completed a public offering of </font><font style="font-family:inherit;font-size:10pt;">7,089,553</font><font style="font-family:inherit;font-size:10pt;"> shares of common at an offering price of </font><font style="font-family:inherit;font-size:10pt;">$67.00</font><font style="font-family:inherit;font-size:10pt;"> per share. We received net proceeds from this offering of </font><font style="font-family:inherit;font-size:10pt;">$448.9 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and commissions paid by us. In addition, we granted the underwriters the right to purchase up to an additional </font><font style="font-family:inherit;font-size:10pt;">1,063,433</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, which was exercised in January 2018, resulting in additional net proceeds to us of </font><font style="font-family:inherit;font-size:10pt;">$67.3 million</font><font style="font-family:inherit;font-size:10pt;">, after underwriting discounts and commissions. After giving effect to the full exercise of the over-allotment option, the number of shares sold by us in the public offering totaled </font><font style="font-family:inherit;font-size:10pt;">8,152,986</font><font style="font-family:inherit;font-size:10pt;"> shares, and net proceeds to us totaled </font><font style="font-family:inherit;font-size:10pt;">$516.2 million</font><font style="font-family:inherit;font-size:10pt;">, after underwriting discounts and commissions.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents and marketable securities of </font><font style="font-family:inherit;font-size:10pt;">$567.8 million</font><font style="font-family:inherit;font-size:10pt;">. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities to be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements.</font></div></div>
CY2017	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the modifications, under the provisions of ASC 605-25, we identified the remaining deliverables under the modified arrangement, and determined the BESP for the undelivered elements as of the modification date. We then allocated the total arrangement consideration, which included the remaining deferred revenue balance at the modification date, any upfront payments received upon modification and other consideration under the modified arrangement that were deemed to be determinable at the modification date, to each unit of accounting relative to our BESP for each unit of accounting.</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001439222-18-000004-index-headers.html	Edgar Link	pending
0001439222-18-000004-index.html	Edgar Link	pending
0001439222-18-000004.txt	Edgar Link	pending
0001439222-18-000004-xbrl.zip	Edgar Link	pending
agio-123117x10k.htm	Edgar Link	pending
agio-20171231.xml	Edgar Link	completed
agio-20171231.xsd	Edgar Link	pending
agio-20171231_cal.xml	Edgar Link	unprocessable
agio-20171231_def.xml	Edgar Link	unprocessable
agio-20171231_lab.xml	Edgar Link	unprocessable
agio-20171231_pre.xml	Edgar Link	unprocessable
agio-ex211x123117.htm	Edgar Link	pending
agio-ex231x123117.htm	Edgar Link	pending
agio-ex232x123117.htm	Edgar Link	pending
agio-ex311x123117.htm	Edgar Link	pending
agio-ex312x123117.htm	Edgar Link	pending
agio-ex321x123117.htm	Edgar Link	pending
agio-ex322x123117.htm	Edgar Link	pending
agiosstockcharta01.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelinea09.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
Agios Pharmaceuticals Inc Stock $agio

2018 Q1 Form 10-K Financial Statement

#000143922218000004 Filed on February 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO Agios Pharmaceuticals Inc Stock $agio

2018 Q1 Form 10-K Financial Statement

#000143922218000004 Filed on February 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
Agios Pharmaceuticals Inc Stock $agio